arrow
X

Xavier Montalbán

Centre d'Esclerosi Multiple de Catalunya
H指数:126
被引数:8.8万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Evaluation of the 2022 international consensus criteria for optic neuritis: the role of clinical features and visual evoked potentials

2022年国际共识标准中视神经炎的临床特征和视觉诱发电位的作用评估

2026-09-040
PRE
Towards a biologically informed description of multiple sclerosis disease course — a roadmap for transition

面向多发性硬化症病程的生物信息学描述——转型路线图

2026-08-030
PRE
Long-term safety and efficacy of ponesimod, an oral S1P1 receptor modulator, in relapsing-remitting multiple sclerosis (RRMS): Results from randomized phase 2b core and extension studies spanning up to 13 years

富马酸非那司提(ponesimod)在复发缓解型多发性硬化(RRMS)中的长期安全性和有效性:来自为期长达13年的随机Ⅱb期CORRE和扩展研究的成果

2026-08-010
PRE
Spider-MS: an individualized polyhedral prediction of multiple sclerosis prognosis

Spider-MS: 一种针对多发性硬化症预后的个性化多面体预测

Brain
IF11.7
2026-06-100
OAAI
How misinformation affects family planning choices for women with multiple sclerosis

错误信息如何影响多发性硬化症女性在计划生育方面的选择

2026-04-080
PRE
A plain language summary on clinical and mechanistic effects of cladribine in relapsing multiple sclerosis: 2-year results from the MAGNIFY-MS study

关于克拉屈滨在复发型多发性硬化中的临床和机制性影响的简明摘要:MAGNIFY-MS研究2年结果

2026-04-010
PRE
Reprogramming autoimmunity: inducing antigen-specific tolerance via apoptotic mimicry in an experimental model of multiple sclerosis

重编程自身免疫:在多发性硬化实验模型中通过凋亡模拟诱导抗原特异性耐受

2025-11-280
OAAI
Six-year safety and efficacy outcomes with first-line ofatumumab in recently diagnosed treatment-naive patients with relapsing multiple sclerosis

首次使用奥法木单抗作为一线治疗新近诊断且未接受过治疗的复发型多发性硬化患者的6年安全性与有效性结果

2025-11-250
OAAI
Long-term safety and efficacy of ozanimod in relapsing multiple sclerosis: Final analysis of the DAYBREAK open-label extension trial

奥扎尼妥(ozanimod)在复发型多发性硬化中的长期安全性与有效性:DAYBREAK开放标签扩展试验的最终分析

2025-11-050
OA
The use of optical coherence tomography and visual evoked potentials in the 2024 McDonald diagnostic criteria for multiple sclerosis

光学相干断层扫描和视觉诱发电位在2024年McDonald多发性硬化诊断标准中的应用

2025-09-170
PRE
Diagnosis of multiple sclerosis: 2024 revisions of the McDonald criteria

多发性硬化症的诊断:2024年麦卡唐纳标准的修订

2025-09-170
OA